StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3037% below fair value
$1.60−0.06 (-3.61%)

Close on Nov 17, 2026Market cap $13.19MP/E –Yield –

Lipocine total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Lipocine's total debt was $1.48M at Mar 31, 2022. For fiscal 2021 it was $2.31M, down 58.7% from the year before. The highest annual figure on record is $10.26M in fiscal 2018.

Annual total debt

PeriodPeriod endValueChange
FY2021Dec 31, 2021$2.31M-58.7%
FY2020Dec 31, 2020$5.59M-21.8%
FY2019Dec 31, 2019$7.15M-30.3%
FY2018Dec 31, 2018$10.26M–
FY2017Dec 31, 2017$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2022Mar 31, 2022$1.48M-69.0%
Q4 FY2021Dec 31, 2021$2.31M-58.7%
Q3 FY2021Sep 30, 2021$3.14M-50.7%
Q2 FY2021Jun 30, 2021$3.96M-37.5%
Q1 FY2021Mar 31, 2021$4.78M-24.8%
Q4 FY2020Dec 31, 2020$5.59M-21.8%
Q3 FY2020Sep 30, 2020$6.36M-19.9%
Q2 FY2020Jun 30, 2020$6.33M-27.3%
Q1 FY2020Mar 31, 2020$6.35M-33.1%
Q4 FY2019Dec 31, 2019$7.15M-30.3%
Q3 FY2019Sep 30, 2019$7.94M-22.2%
Q2 FY2019Jun 30, 2019$8.72M-13.9%
Q1 FY2019Mar 31, 2019$9.49M-5.7%
Q4 FY2018Dec 31, 2018$10.26M–
Q3 FY2018Sep 30, 2018$10.19M–
Q2 FY2018Jun 30, 2018$10.13M–
Q1 FY2018Mar 31, 2018$10.06M–
Q4 FY2017Dec 31, 2017$0–

More Lipocine figures

See a number that looks wrong?